OR WAIT null SECS
Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.
Quality considerations have always been vital to biotherapeutic developers and CMOs. Yet, in 2016, it seems that these considerations are taking on a new emphasis. One of the main industry trends seen this year-increased attention to continuous bioprocessing-is at least partly driven by the potential for improved product quality.